BIIBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
BIOGEN INC.
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on Jul 29, 2026
$233.48+0.83 (+0.36%)
Close on Oct 19, 2026
- Market cap
- $34.65B
- P/E (TTM)
- 25.1
- Dividend yield
- –
Share price
+$90.48 (+63.27%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
BIOGEN INC. grew revenue 1.2% to $9.94B over the twelve months to Mar 31, 2026. Free cash flow was $2.42B, down 0.6% from a year earlier.
Revenue
$9.94B
+1.2% vs. a year earlier
Free cash flow
$2.42B
-0.6% vs. a year earlier
EPS, diluted
$9.32
-8.0% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Mar 31, 2026
Valuation
- Market cap
- $34.65B
- P/E ratio
- 25.1
- Price to sales
- 3.49
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- 6.99%
Fundamentals
- Revenue
- $9.94B
- Net income
- $1.37B
- EPS, diluted
- $9.32
- Free cash flow
- $2.42B
- Diluted shares
- 148M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$9.94B+1.2% YoY
Gross profit
$7.50B+1.1% YoY
Operating income
–
Net income
$1.37B-7.3% YoY
EPS, diluted
$9.32-8.0% YoY
Free cash flow
$2.42B-0.6% YoY
Reported periodTrailing twelve months